Logo-ipp

Immunopathol Persa. 2021;7(2): e25. doi: 10.34172/ipp.2021.25

Review

High risk individuals in COVID-19 pandemic; an updated review

Rojin Chegini 1 ORCID, Alireza Bolurian 2,3 ORCID, Zahra Mojtahedi 4 ORCID, Masoud Hafizi 5 * ORCID

Cited by CrossRef: 1

1- Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib. PHAR. 2023;70(4):1177 [Crossref]